
FDA green-lights Alembic’s cholesterol drug
pharmafile | May 15, 2017 | News story | Sales and Marketing | Alembic, FDA, cholesterol
Alembic Pharmaceuticals has announced that its fenofibric acid delayed-release capsules have been approved by the FDA for reducing high cholesterol and increasing good cholesterol.
The capsules are indicated as supplementary to primary therapy in the treatment of high triglyceride in patients with hypertriglyceridemia, as well as to lower high LDL-C levels, total cholesterol, and to increase high-density lipoprotein – also known as ‘good’ cholesterol.
The firm revealed the news via a statement which read: “The company has received US Food and Drug Administration (FDA) approval for its abbreviated new drug application (ANDA) for its Fenofibric Acid Delayed-Release Capsules, 45mg and 135mg.” The capsules are therapeutically equivalent to Abbvie’s Trilipix, the reference listed drug product.
The capsules were approved under an abbreviated new drug application with the FDA; Alembic currently has 56 such approvals with the regulator.
Matt Fellows
Related Content

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance
Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation
Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary …

Johnson & Johnson submits robotic surgical system for De Novo classification
Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …






